NIVOLUMAB

Information current as at: 1 June 2026

Legend: Completed N In progress Not applicable N Yet to commence

Submission Details

Brand name:
  • Opdivo®
Form and strength:

Please search for and view the meeting agenda from the relevant meeting for more information

Submission sponsor:
BRISTOL-MYERS SQUIBB AUSTRALIA PTY LTD
Condition/indication:
(therapeutic use)
  • Malignant melanoma Non-Small Cell Lung Cancer (NSCLC) Renal Cell Carcinoma (RCC) Squamous Cell Carcinoma of the Head and Neck (SCCHN) Urothelial Carcinoma (UC) Oesophageal / Gastro-oesophageal cancers(OC/GC)
Listing requested:
Please see meeting agenda for more information
Funding program:
Please see meeting agenda for more information
Request authority level:
Please see meeting agenda for more information
PBAC Submission type:
New PBS listing (–)
Comment:
--
Other PBAC consideration:
--

Progress Details

Submission received for:
March 2026 PBAC meeting
Opportunity for consumer comment:
Open 19/11/2025 and close 21/01/2026 (see PBS Website)
PBAC meeting:
Held on 11/03/2026
PBAC outcome published:
Recommended (see PBAC Outcomes)
Notice of intent submitted:
Awaiting lodgement from pharmaceutical company
5Lodgement of required documentation:
6Agreement to listing arrangements:
Has not yet commenced
7Government processes:
Has not yet commenced
8Medicine listed on the PBS:
Has not yet occurred
Glossary

PBAC Outcome

PBAC Recommendation:

Not yet published

Public Summary Document:
Not yet available
Case ID
a1171
Page last updated
30 April 2026
Return to the Medicine Status Listing
v.9.19